CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
Note: The pCODR Provincial Advisory Group, PAG, has submitted a Request for Advice for this drug & indication on April 18, 2017. Please see the RFA: Inlyta for Metastatic Renal Cell Carcinoma details page for more information: https://www.cadth.ca/rfa-inlyta-metastatic-renal-cell-carcinoma.
| Project Number | PC0013-000 |
|---|---|
| Brand Name | Inlyta |
| Generic Name | Axitinib |
| Strength | 1mg and 5mg |
| Tumour Type | Genitourinary |
| Indication | Metastatic Renal Cell Carcinoma |
| Funding Request | For the treatment of patients with metastatic renal cell carcinoma (RCC) of clear histology after failure of prior systemic therapy with either a cytokine or the VEGFR-TKI, sunitinib |
| Review Status | Complete |
| Pre Noc Submission | No |
| NOC Date | July 12, 2012 |
| Manufacturer | Pfizer Canada Inc. |
| Sponsor | Pfizer Canada Inc. |
| Submission Date | August 16, 2012 |
| Submission Deemed Complete | August 23, 2012 |
| Submission Type | Initial |
| Prioritization Requested | Not Requested |
| Stakeholder Input Deadline ‡ | August 30, 2012 |
| Check-point meeting | October 10, 2012 |
| pERC Meeting | December 20, 2012 |
| Initial Recommendation Issued | January 14, 2013 |
| Feedback Deadline ‡ | January 28, 2013 |
| pERC Reconsideration Meeting | February 21, 2013 |
| Final Recommendation Issued | March 7, 2013 |
| Notification to Implement Issued | March 22, 2013 |
| Therapeutic Area | Metastatic Renal Cell Carcinoma |
| Recommendation Type | Reimburse |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
